Research · 10 min read
What Repackaging and Relabeling a Drug Actually Are
Moving a finished medication into a different container is neither manufacturing it nor compounding it. It is a third act with its own definition, and the rules that cover it are not the rules most people assume.
Key takeaways
- Repackaging moves a finished drug into a different container without manipulating, changing, or affecting its composition or formulation.
- Reconstituting, diluting, mixing, or combining with another ingredient is not repackaging, by FDA's own statement.
- Relabeling changes the label without repacking, and excludes stickers added for delivery, customer identification, or inventory management.
- Drugs that are repackaged are not subject to sections 503A and 503B, so the compounding exemptions do not reach them.
- FDA published a set of conditions under which it does not intend to act, and states that its guidances generally do not create enforceable duties.
- An outsourcing facility's repackaged container is meant to say it was repackaged, by whom, from what, and with what expiry.
Answer first: it is defined by what it does not change
Repackaging has a written federal definition, and the whole of it turns on one idea. It is taking a finished drug product, or an unfinished drug, out of the container it was placed in for commercial distribution and putting it into a different container.
The definition then adds the limit that does the work. That move counts as repackaging only if it happens without manipulating, changing, or affecting the composition or formulation of the drug.
Relabeling is the companion act. It means changing or altering the existing label or labeling on a drug or a drug package, without repacking it. Stickers added purely for delivery, customer identification, or inventory management are carved out.
So a repackager is not a maker. The substance in the container is meant to be the same substance that left the original plant, in a different vessel or under a different label.
The line between repackaging and compounding
FDA draws that line in its own guidance on the subject, and it draws it in one sentence. If a drug is reconstituted, diluted, mixed, or combined with another ingredient, that act is not repackaging.
The agency does treat one kind of pooling as repackaging. Placing the contents of several containers of the same finished drug product into one container qualifies, as long as that container does not include other ingredients.
The guidance also says plainly that it does not apply to compounding, and points readers to separate documents for that. The two subjects are neighbors and they are not the same subject.
That distinction is worth carrying into any conversation about an injectable. A vial whose contents were transferred without alteration and a preparation built from a bulk powder are different products of different processes, even when the molecule named on the front is the same.
The sentence that surprises people
Compounding gets its legal breathing room from two sections of federal law. Repackaging does not sit under either of them, and FDA says so in as many words: drugs that are repackaged are not subject to sections 503A and 503B of the Act.
The consequence is spelled out in the next line. Drug products repackaged by a state-licensed pharmacy, a federal facility, or an outsourcing facility are not eligible for the exemptions those sections provide.
What applies instead is the ordinary law of drugs. FDA states that repackaged products are generally subject to the premarket approval, misbranding, adulteration, and supply chain security provisions of the Act. It names the approval section, the adequate-directions-for-use section, the manufacturing practice section, and the tracing section.
That is the opposite of the intuition most people bring to it. Repackaging looks like the smaller act, and legally it carries a heavier default load than compounding does.
What FDA published instead of a permission
Rather than a rule, the agency issued a policy of conditions. Its guidance describes the circumstances in which it does not intend to take action for violations of the approval, adequate-directions and tracing sections when certain facilities repackage.
The manufacturing practice section is treated separately. FDA says it does not intend to take action there for repackaging done by a state-licensed pharmacy or a federal facility, and that carve-out does not extend to an outsourcing facility.
The document is honest about its own weight. It states that FDA guidances generally do not establish legally enforceable responsibilities, that they describe the agency's current thinking, and that the word should means suggested or recommended rather than required.
Read carefully, that is a description of restraint, not a grant of authority. It tells a facility what FDA has said it will overlook, and it leaves the underlying provisions standing.
The conditions, in the order a buyer would care about
The first condition is about the starting material. The product being repackaged has to be a prescription drug that is approved. It may instead be an unapproved drug that appears on the federal shortage list, distributed during the listing or in the thirty days after it.
The next three are about the place and the paperwork. Repackaging happens in a state-licensed pharmacy, a federal facility, or an outsourcing facility, by or under the direct supervision of a licensed pharmacist.
A pharmacy or federal facility adds one more step. It distributes only after receiving a valid prescription for an identified individual patient, directly from the prescribing practitioner or the patient. That condition does not apply to an outsourcing facility.
The remaining conditions govern the object itself. Repackaging, storage and shipping must not conflict with the approved labeling. Storage instructions carry over to the new label. The container has to be suitable through the assigned date, and the product must not be one on the federal list of drugs withdrawn or removed as unsafe or ineffective.
Two conditions are about who may then touch it. The product is not sold or transferred by any entity other than the one that repackaged it, and it is distributed only in states where that facility meets all applicable state requirements.
The single-container exception, which is the one that matters here
One condition carries an exception written for exactly the situation people ask about. Consider a product packaged in a single-dose vial that is repackaged into multiple units. The conditions allow a departure from the statements designating it as single-dose or single-use, and from related language such as an instruction to discard the remaining contents.
The exception is narrow, and the guidance fences it. Repackaging from a single-dose vial still has to avoid conflicting with other language in the approved labeling, and storage conditions are the example FDA gives.
That is why the same act can be inside the policy in one respect and outside it in another. Splitting the vial may be contemplated; freezing it, or exposing it to something the labeling warns against, is not.
A footnote in the same document also settles a question about identification. The code number belonging to the original approved product should not be placed on the repackaged one.
What an outsourcing facility has to print when it repackages
For outsourcing facilities the conditions get specific about the label on the immediate container. It carries a statement that the product was repackaged by the named facility, along with that facility's address and telephone number.
The rest of the immediate label is an identity list. It names the established name of the original product, the lot or batch number, and the dosage form and strength. It also carries a statement of quantity or volume, the date it was repackaged, the assigned expiry, and storage and handling instructions.
Two more statements sit on that container. One reads that the product is not for resale, and a further statement about office use appears where the facility distributes other than against a prescription for an individually identified patient.
The outer package carries what will not fit inside. That includes the active and inactive ingredients where the immediate label is too small, directions for use, and the agency's adverse event reporting address and telephone number.
The conditions do not stop at the label. A repackaging outsourcing facility reports the products to FDA twice a year, each June and December. The report gives the active ingredients and their source, the strength, the dosage form and route, the package description, and the number of units produced.
Why a buyer runs into the word at all
Mail-order programs describe their supply arrangements in loose language, and repackaging is one of the things that loose language can be covering. A facility that transfers a finished product into new containers is doing something real, regulated, and different from making a drug from scratch.
The word also marks a boundary the conditions themselves draw. FDA's first condition limits the policy to a product that is approved, or one that is unapproved and sits on the federal shortage list within a stated window. Moving a substance into a new container does not change what that substance is.
None of that is a verdict on any company. The value of knowing the definition is that it turns a vague sentence into a question with a checkable answer.
Ask which entity put the product into the container that arrived, whether anything was added or diluted along the way, and what date that container carries. Those three answers separate three different processes.
What this settles, and what it does not
It settles the vocabulary. Repackaging moves a finished drug without altering it, relabeling changes the label without repacking, and compounding produces something new. Three words, three acts, three sets of rules.
It also settles the legal shape. The compounding exemptions do not reach a repackaged product, and a nonbinding policy of conditions is what stands in their place.
What it does not settle is whether any particular container in any particular box went through any of these processes. That is a question for the facility named on the label and for the program that sold it.
A label that names nobody has answered none of it. That is the practical use of all of the above.
Sources
- Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities — Guidance for IndustryFDA's description of repackaging as taking a finished drug product from the container in which it was distributed by the original manufacturer and placing it into a different container without further manipulation; the treatment of pooling several containers of the same finished product into one container as repackaging, provided that container includes no other ingredients; the statement that reconstituting, diluting, mixing or combining with another ingredient is not repackaging; the statement that the guidance does not apply to the compounding of drug products; the statement that drugs which are repackaged are not subject to sections 503A and 503B of the Act and are therefore not eligible for the exemptions those sections provide; the list of provisions repackaged products remain generally subject to, covering approval, adequate directions for use, current good manufacturing practice and supply chain security; the general policy of not intending to take action on three of those provisions where a state-licensed pharmacy, federal facility or outsourcing facility repackages in accordance with the conditions, and on the manufacturing practice provision only for a state-licensed pharmacy or federal facility; the numbered conditions covering the approved or shortage-listed starting product, the type of facility, direct supervision by a licensed pharmacist, the identified-patient prescription condition and its inapplicability to outsourcing facilities, the prohibition on conflicting with approved labeling with its single-dose vial exception, container suitability, the carrying over of storage and handling instructions, the assigned date, the withdrawn or removed products list, the bar on sale or transfer by another entity, and distribution only in states where the facility meets state requirements; the outsourcing facility labeling conditions for the immediate container and the outer package including the adverse event reporting address and telephone number; the twice-yearly June and December product report; and the document's own statement that FDA guidances generally do not establish legally enforceable responsibilities and that should means suggested or recommended rather than required.
- Title 21 Code of Federal Regulations section 207.1, What definitions and interpretations of terms apply to this part?The definition of repack or repackage as taking a finished drug product or unfinished drug from the container in which it was placed in commercial distribution and placing it into a different container without manipulating, changing, or affecting the composition or formulation of the drug; the definition of relabel as changing or altering the existing label or labeling on a drug or drug package without repacking it, together with its exclusion of information affixed solely for delivery to a customer, customer identification, or inventory management; the definitions of repacker and relabeler as persons owning or operating an establishment that carries out those acts; and the statement that the term manufacture is defined and used separately from the terms relabel, repackage and salvage.
- Human Drug Compounding Policies and RulesThat FDA publishes the repackaging guidance within its own set of human drug compounding policies and rules, alongside separate documents on the mixing, diluting and repackaging of biological products and on the compounding and repackaging of radiopharmaceuticals, which is how the guidance cited above was located rather than by constructing an address for it.
Frequently asked questions
Is repackaging the same as compounding?
No, and FDA's guidance on repackaging says so directly. Repackaging is taking a finished drug product out of the container it was distributed in and placing it into a different container without manipulating, changing, or affecting the composition or formulation of the drug. The agency adds that if a drug is reconstituted, diluted, mixed, or combined with another ingredient, that act is not repackaging. The guidance also states that it does not apply to the compounding of drug products, and points to separate documents for that subject.
Do the compounding rules cover a repackaged drug?
They do not. FDA's guidance states that drugs which are repackaged are not subject to sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Products repackaged by a state-licensed pharmacy, a federal facility, or an outsourcing facility are therefore not eligible for the exemptions those sections provide. In their place the agency describes a policy of enforcement conditions, and says in the same document that its guidances generally do not establish legally enforceable responsibilities.
Can a single-dose vial be repackaged into several units?
FDA's conditions contemplate it and fence it. One condition requires that repackaging, storage and shipping not conflict with the approved labeling. For a product packaged in a single-dose vial and repackaged into multiple units, the conditions allow a departure from two things. One is the statements designating the product as single-dose or single-use, and the other is related language such as discarding remaining contents. Other approved labeling still applies, and the guidance names storage conditions as its example.
Does the guidance mean repackaging is approved by FDA?
No. The document describes circumstances in which the agency does not intend to take action, which is a statement about enforcement rather than about approval. The guidance states on its own face that guidances describe the agency's current thinking, generally do not establish legally enforceable responsibilities, and use the word should to mean recommended rather than required. Repackaged products remain generally subject to the approval, misbranding, adulteration and supply chain security provisions of the Act.
How would I know whether what I received was repackaged?
For an outsourcing facility the conditions ask for a statement on the immediate container saying the product was repackaged by that named facility, with its address and phone number. The same label carries the established name of the original product, a lot or batch number, the dosage form and strength, and a quantity or volume. It also carries the date it was repackaged, an expiry, and storage instructions. A container carrying none of that has told you nothing about its route, and the program that sold it is the party to ask.